MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more
Market Cap & Net Worth: MOLECULAR PARTNERS ADS/1 (6ML0)
MOLECULAR PARTNERS ADS/1 (F:6ML0) has a market capitalization of $144.34 Million (€140.62 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #19863 globally and #2119 in its home market, demonstrating a -9.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MOLECULAR PARTNERS ADS/1's stock price €3.76 by its total outstanding shares 37399152 (37.40 Million).
MOLECULAR PARTNERS ADS/1 Market Cap History: 2021 to 2026
MOLECULAR PARTNERS ADS/1's market capitalization history from 2021 to 2026. Data shows change from $660.29 Million to $144.34 Million (-25.89% CAGR).
MOLECULAR PARTNERS ADS/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MOLECULAR PARTNERS ADS/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6ML0 by Market Capitalization
Companies near MOLECULAR PARTNERS ADS/1 in the global market cap rankings as of March 19, 2026.
Key companies related to MOLECULAR PARTNERS ADS/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MOLECULAR PARTNERS ADS/1 Historical Marketcap From 2021 to 2026
Between 2021 and today, MOLECULAR PARTNERS ADS/1's market cap moved from $660.29 Million to $ 144.34 Million, with a yearly change of -25.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €144.34 Million | +1.62% |
| 2025 | €142.04 Million | -25.70% |
| 2024 | €191.18 Million | +31.75% |
| 2023 | €145.11 Million | -31.89% |
| 2022 | €213.06 Million | -67.73% |
| 2021 | €660.29 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of MOLECULAR PARTNERS ADS/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.34 Million USD |
| MoneyControl | $144.34 Million USD |
| MarketWatch | $144.34 Million USD |
| marketcap.company | $144.34 Million USD |
| Reuters | $144.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.